Filtering by:
Soft Tissue SarcomaFDA Approves Tazverik (Tazemetostat) for Epithelioid Sarcoma
The US Food and Drug Administration (FDA) has approved Tazverik (tazemetostat) to treat adults and children 16 and older with epithelioid sarcoma, a rare cancer which accounts for less than 1% of all soft tissue sarcomas.
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
Cancer Facts and Figures: Death Rate Down 25% Since 1991
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
FDA Approves Lartruvo for Soft Tissue Sarcoma
The US Food and Drug Administration (FDA) has approved Lartruvo (olaratumab) for advanced soft tissue sarcoma.
FDA Approves Halaven (Eribulin) for Liposarcoma
The US Food and Drug Administration (FDA) has approved the chemotherapy drug Halaven (eribulin) to treat liposarcoma, a type of soft tissue sarcoma.